Latest news with #LeroyLeo
Business of Fashion
12-05-2025
- Health
- Business of Fashion
Zepbound Beats Wegovy in First Head-to-Head Trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. Lilly reported in December that its obesity drug had already met the main goal, leading to 47 percent more weight loss than those who received Wegovy. Full data from the study was reported by the company in a press release and presented at the European Congress on Obesity. The data is the first head-to-head trial comparing the wildly popular medicines, and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market estimated to reach more than $150 billion annually by the next decade. It comes days after CVS Health's decision to drop Zepbound from some lists of medicines it covers for reimbursement, instead favouring Wegovy. Zepbound helped nearly 25 percent more participants lose more than 15 percent of their weight compared to Wegovy, Lilly said on Sunday. The trial also showed that treatment with Zepbound achieved a superior average waist circumference reduction of 18.4 centimetres, while those treated with Wegovy saw an average reduction of 13 centimetres. While Lilly's drug mimics two gut hormones to help reduce weight, Wegovy has a single mode of action. US approvals for Zepbound and Wegovy were based on separate trials in which Lilly's drug helped patients lose more than 22 percent of their weight after 72 weeks, while Wegovy led to 15 percent weight loss after 68 weeks. By Christy Santhosh; Edited by Leroy Leo Learn more: CVS Drops Lilly's Zepbound as Preferred Drug in Novo Win Starting July 1, Wegovy, not Zepbound, will be preferred on CVS Caremark's standard formulary.
Yahoo
07-05-2025
- Business
- Yahoo
Top potash producer Nutrien misses first-quarter profit estimates
(Reuters) - Nutrien fell short of Wall Street expectations for first-quarter profit on Wednesday, as the top potash producer struggled with lower sales volumes. The Saskatoon, Canada-based firm posted an adjusted profit of 11 cents per share for the quarter ended March 31, compared with the analysts' average estimate of 31 cents per share, according to data compiled by LSEG. (Reporting by Tanay Dhumal in Bengaluru; Editing by Leroy Leo)
Zawya
12-03-2025
- Business
- Zawya
Mideast Stocks: Gulf markets end mixed on Ukraine ceasefire hopes, tariff fears
Stock markets in the Gulf ended mixed on Wednesday, buoyed by Ukraine's readiness to support a proposal for a 30-day ceasefire with Russia, but investor optimism was tempered by concerns over the economic fallout of U.S. tariffs. Saudi Arabia's benchmark index eased 0.1%, hit by a 3.3% fall in ACWA Power Co and a 2.5% decrease in Saudi Arabian Mining Company. Elsewhere, oil giant Saudi Aramco was down 0.4%. Fitch Ratings expects Saudi Arabia's deficit to widen as Aramco's dividend normalizes. Dubai's main share index gained 0.7%, with blue-chip developer Emaar Properties rising 2.3% and sharia-compliant lender Dubai Islamic Bank increasing 3.1%. In Abu Dhabi, the index finished 0.4% higher. Investors are waiting for U.S. Consumer Price Index data at 1230 GMT to gauge the Federal Reserve's next move on interest rates. Monetary policy in the six-member Gulf Cooperation Council is usually guided by the Fed's decisions, as most regional currencies are pegged to the dollar. The Qatari index dropped 0.4%, hit by a 5.1% slide in telecom firm Ooredoo, as the stock traded ex-dividend. Outside the Gulf, Egypt's blue-chip index closed 0.4% higher, with GB Auto advancing 8.8%. The International Monetary Fund approved the disbursement of $1.2 billion to Egypt following completion of the fourth review of the country's $8 billion economic reform programme, after allowing Egypt to waive a primary budget surplus target. SAUDI ARABIA fell 0.1% to 11,705 Abu Dhabi rose 0.4% to 9,416 Dubai gained 0.7% to 5,157 QATAR dropped 0.4% to 10,438 EGYPT was up 0.4% to 31,049 BAHRAIN added 0.2% to 1,967 OMAN lost 0.9% to 4,364 KUWAIT was up 0.1% to 8,536 (Reporting by Ateeq Shariff in Bengaluru; Editing by Leroy Leo)
Reuters
05-03-2025
- Business
- Reuters
Jazz Pharmaceuticals to buy Chimerix for $935 million
March 5 (Reuters) - Jazz Pharmaceuticals (JAZZ.O), opens new tab will acquire biotech firm Chimerix (CMRX.O), opens new tab for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo
